Skip to content
Aperlena
Free alerts

Spain - Pharmaceutical products - Framework agreement for the supply of medicines without competition for hospitals of the Cantabrian Health Service (active ingredients Luspatercept, Mavacamten, Fedratinib, Belatacept, Abatacept, Deucravacitinib, Ipilimumab, Ozanimod)

Original España - Productos farmacéuticos - Acuerdo Marco para el suministro de medicamentos sin competencia para los hospitales del Servicio Cántabro de Salud (Principios activos Luspatercept, Mavacamten, Fedratinib, Belatacept, Abatacept, Deucravacitinib, Ipilimumab, Ozanimod).

Awarded Contract award

Key facts

Awarded
Winner
BRISTOL-MYERS SQUIBB, S.A.
Estimated value
€22,087,489
Buyer
Servicio Cántabro de Salud
Where
Spain Cantabria
Procedure
Negotiated procedure The buyer selects candidates, then negotiates the offers before choosing. Full entry Above the EU threshold A contract large enough that EU-wide rules apply and it must be published on TED. Full entry
CPV code The EU's common vocabulary for what is being bought: an eight-digit code every notice carries. Full entry
33600000 Pharmaceutical products
Original language
Spanish
Source
via TED - Tenders Electronic Daily (Publications Office of the EU), verified 9 hours ago
Notice number
657724-2026
Watch this tender

Bidding is closed. An award or a correction on this notice: an email when the register sees it. Log in

  1. Awarded
  2. Published

Summary

Machine-generated summary

The Cantabrian Health Service has awarded a framework agreement for supplying medicines without competition to its hospitals. The agreement covers eight lots of branded medicines: Reblozyl (Luspatercept), Camzyos (Mavacamten), Inrebic (Fedratinib), Nulojix (Belatacept), Orencia (Abatacept), Sotyktu (Deucravacitinib), Yervoy (Ipilimumab) and Zeposia (Ozanimod hydrochloride). The contract was awarded to BRISTOL-MYERS SQUIBB, S.A. with an estimated value of EUR 22,087,488.96. The award date given in the record is 2026-08-21. The contract status is recorded as awarded.

Description

Acuerdo Marco para el suministro de medicamentos sin competencia para los hospitales del Servicio Cántabro de Salud (Principios activos Luspatercept, Mavacamten, Fedratinib, Belatacept, Abatacept, Deucravacitinib, Ipilimumab, Ozanimod). Lote 1. Reblozyl (Luspatercept); Lote 2. Camzyos (Mavacamten); Lote 3. Inrebic (Fedratinib); Lote 4. Nulojix (Belatacept); Lote 5. Orencia (Abatacept); Lote 6. Sotyktu (Deucravacitinib); Lote 7. Yervoy (Ipilimumab); Lote 8. Zeposia (Ozanimod hidrocloruro)

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Report an error in this notice

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 9 hours ago

View the official notice

More from this buyer

Full buyer profile

3 open tenders right now

Recent awards

Similar tenders

1

day left

Supply of non-latex surgical gloves

Spain Medical equipment & pharmaceuticals Dirección Gerencia de Mutualia, Mutua Colaboradora con la Se...

€3,318

est. value

Market context

Avg. open tender · Medical equipment & pharmaceuticals
€11,085,809
9,975 open across Europe right now 99% above sector average
Buyer track record on Aperlena
481 notices tracked · 449 awarded
€61,006,781 in awarded contracts

Never miss a tender like this

886 new notices in Medical equipment & pharmaceuticals in Spain in the last 7 days. Get an email when new ones appear. Free.

Set up my alert
Open notice

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
/
Search from any page
Ctrl K
Search from any page
?
Show these shortcuts
Esc
Close

Start from a question

Browse by sector

Index

Close
Log in

Language